BRCA1 Mutation Clinical Trial
Official title:
Radical Fimbriectomy for Young BRCA Mutation Carriers at Risk of Pelvic Serous Carcinoma
Some BRCA-mutated women are reluctant to undergo laparoscopic bilateral salpingo-oophorectomy. The goal of the bilateral laparoscopic radical fimbriectomy the investigators suggest, is to suppress the tubal source of possible dysplastic cells from which can stem this high grade tumor, while preserving a natural ovarian hormonal secretion.
Most of ovarian carcinomas related to BRCA 1 or 2 mutations are of fallopian tube origin and especially from its distant part called the fimbria. These tubal, ovarian or primary peritoneal carcinomas are quite always of high grade serous type. They cannot be effectively screened due to the quickness of their evolution. In this context, a laparoscopic bilateral salpingo-oophorectomy (BSO) is the recommended prophylactic procedure. Some BRCA-mutated women are reluctant to undergo this procedure considering the numerous adverse effects on body and quality of life, especially when hormonal replacement is forbidden. This refusal makes them at risk of developing a serous pelvic carcinoma. The goal of the bilateral laparoscopic radical fimbriectomy the investigators suggest, is to suppress the tubal source of possible dysplastic cells from which can stem this high grade tumor, while preserving a natural ovarian hormonal secretion ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Withdrawn |
NCT03032614 -
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
|
Phase 2 | |
Not yet recruiting |
NCT04055038 -
Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)
|
Phase 2/Phase 3 | |
Recruiting |
NCT04566952 -
Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer
|
Phase 2 | |
Recruiting |
NCT04499534 -
BRCA1/2 Flu Vaccine
|
||
Recruiting |
NCT05537844 -
Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma
|
||
Active, not recruiting |
NCT03685331 -
HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer
|
Phase 1 | |
Recruiting |
NCT05097274 -
The GENPET Study - An Imaging Study of FCH-PET-CT in Men With Prostate Cancer and a BRCA Gene Mutation.
|
||
Completed |
NCT03428399 -
Depression and Body Image Distress Following Mastectomy With Reconstruction
|
||
Completed |
NCT02957981 -
The Genetic Education for Men Trial: Web-Based Education vs. Standard Care
|
N/A | |
Recruiting |
NCT04556071 -
Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer
|
Phase 2 | |
Completed |
NCT04651920 -
A Study on Association Between HR Genes and the HRD Status in Chinese Epithelial Ovarian Cancer
|
||
Completed |
NCT02974842 -
Pre-Salpingo-Oophorectomy Pilot Study of MAKO 7 Device Performance
|
||
Active, not recruiting |
NCT03351803 -
BRCA Founder OutReach (BFOR) Study
|
||
Withdrawn |
NCT05062174 -
Breast Cancer BRCA1 Carriers: a Pilot Study
|
||
Suspended |
NCT04151368 -
Surgical and Patient Reported Outcomes of Robotic Nipple-Sparing Mastectomy
|
N/A | |
Active, not recruiting |
NCT04273542 -
Interest of Broadband Spectroscopy Analysis by Infrared Laser on Liquid Biopsies in Breast Cancer Screening
|
N/A | |
Recruiting |
NCT05694715 -
Combination Therapy in Cancers With Mutations in DNA Repair Genes
|
Phase 1 | |
Recruiting |
NCT06395519 -
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
|
Phase 1 | |
Recruiting |
NCT05410951 -
LobularCard Trial: Searching for Novel Germline Mutations in Lobular Breast Cancer Patients
|